Teva rolls out generic Truvada, Atripla
Teva is offering two combination HIV treatments: emtricitabine and tenofovir disoproxil fumarate tablets, and efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets.
The products are the generics of Gilead’s Truvada, and Gilead’s Atripla, respectively.
“As the global leader in producing and supplying generics, Teva is excited to launch these medications which further our commitment to delivering more treatment options to patients,” said Brendan O’Grady, Teva executive vice president, North America commercial. “These products, in addition to our more than 10 HIV-related medications already on the World Health Organization’s Essential Medicines list, represent Teva’s continued pursuit of treatments for HIV to improve health outcomes for the HIV community. During the COVID-19 pandemic, access to treatment is more essential than ever for those who are immunocompromised and at risk of developing more severe disease.”
Emtricitabine and tenofovir disoproxil fumarate tablets are indicated for the treatment of HIV-1 infection when used with other anti-HIV-1 medicines in adults and children who weigh at least 37 pounds (at least 17 kilograms); and HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kilograms)
Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are indicated for the treatment of HIV-1 infection in people who weigh at least 88 pounds (40 kilograms), alone as a complete regimen, or in combination with other anti-HIV-1 medicines.
Both medications are combination treatments available as a single pill with similar safety profiles to their reference products, the company said.
Emtricitabine and tenofovir disoproxil fumarate tablets are expected to be available through retailers and wholesalers at a wholesale acquisition cost of $48.51 per tablet.
Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are expected to be available through retailers and wholesalers at a wholesale acquisition cost of $78.86 per tablet.
Actual costs to individual patients and providers are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patient’s insurance payer and eligibility for participation in the assistance program.